<DOC>
	<DOC>NCT01325740</DOC>
	<brief_summary>The study will consist of a Screening period (up to 14 days), a Treatment period, and a Follow-Up period. Sixteen subjects will be enrolled into two sequential dose cohorts - 10 or 30 mg (or matching placebo) across four study centers.</brief_summary>
	<brief_title>A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Male subjects 18 to 50 years of age, inclusive. Molecular documentation of the full fragile X mutation. Subjects with a history of seizure disorder who are, in the opinion of the Investigator and Medical Monitor, not currently considered to be well controlled. Subjects currently being treated with psychoactive medications (including stimulants and anxiolytics). Subjects with any condition, including alcohol and drug abuse, which might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own wellbeing. 4. Subjects who plan to initiate or change pharmacologic or nonpharmacologic interventions during the course of the study. Subjects who, in the Investigator's opinion, might not be suitable for the study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>